Scotiabank lowered the firm’s price target on Castle Biosciences (CSTL) to $40 from $44 and keeps an Outperform rating on the shares. The company raised its full year guidance despite DecisionDx-SCC no longer being reimbursed by Medicare and the discontinuation of IDgenetix, the analyst tells investors. The company remains on track to launch a therapy guidance test for atopic dermatitis by the end of 2025, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences announces new data on DecisionDx-UM
- Castle supporting series of initiatives to raise awareness of skin cancer
- Castle Biosciences: Strong Market Position and Growth Potential in Cancer Diagnostics
- Castle Biosciences Reports Strong Growth Amid Challenges
- Castle Biosciences price target lowered to $35 from $40 at Lake Street